Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Huntingdon’s disease

    - PMLiVE

    EMA reaffirms guidance on paracetamol use during pregnancy

    The guidance follows recent US comments about a possible link to autism

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    EMA orphan drug designation given to ReAlta for graft-versus-host disease therapy

    This follows preliminary results from the company's ongoing phase 2 trial

    - PMLiVE

    Organon/Henlius announce EMA validation for Perjeta biosimilar HLX11

    The reference medicine holds approvals for multiple HER2-positive breast cancer indications

    Biogen Idec building

    Biogen’s higher dose spinal muscular atrophy regimen accepted for review by EMA/FDA

    The neuromuscular disease affects approximately one in every 10,000 babies worldwide

    Challenges for orphan medicines entering the European market

    We explore the various challenges facing orphan medicines entering the European market and offer solutions to help improve patient access.

    Petauri Evidence

    - PMLiVE

    Pfizer/BioNTech’s KP.2-adapted COVID-19 vaccine receives CHMP recommendation

    The updated vaccine was shown to generate an improved response against currently circulating variants

    - PMLiVE

    What are “orphan drugs” and how do we navigate the challenges of writing about them?

    The first in our 'Ask Alex' series, where Principal Medical Writer, Dr Alexandra Loveday answers some frequently asked questions about Medcomms. This week, she takes a look at 'orphan drugs',...

    Mednet

    - PMLiVE

    uniQure’s investigational gene therapy shown to slow Huntington’s disease progression

    The neurodegenerative disorder affects approximately 70,000 people in Europe and the US

    tijana being interviewed

    Envision Analogue – An Introduction

    Powered by primary payer market research, Envision is an online platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive...

    Genesis Research Group

    - PMLiVE

    AstraZeneca’s Tagrisso combination receives CHMP recommendation for advanced lung cancer

    More than 450,000 people are diagnosed with lung cancer every year in Europe

    - PMLiVE

    Pfizer’s one-time haemophilia B therapy Durveqtix receives CHMP recommendation

    More than 38,000 people worldwide are currently affected by the inherited bleeding disorder

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links